Mayne Pharma Group (AU:MYX) has released an update.
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Mayne Pharma Group has announced a significant change in the securities interest of its director, Shawn Patrick O’Brien. As of December 2, 2024, O’Brien acquired an additional 301,455 Performance Rights and 35,170 RSU Performance Rights, increasing his direct holdings. This change reflects O’Brien’s growing stake in the company, potentially signaling confidence in Mayne Pharma’s future performance.
For further insights into AU:MYX stock, check out TipRanks’ Stock Analysis page.
